Lambda Therapeutic Research has announced successful closure of an Inspection/Audit of 5 parallel multi-centric site inspections by the US Food and Drug Administration (USFDA) with zero 483s. This achievement reiterates our constant endeavor and commitment towards Quality in Patient based Clinical Trials in India. The inspection/audit was conducted for Clinical trials carried out between 15th and 26th Oct for two Atopic Dermatitis studies and one Chronic Myeloid Leukemia study. With this successful closure, we have now cleared 38 multi-centric Inspections/Audits by the USFDA for Patient based trials carried out for US submission across various clinical sites & geographies we have developed in India.